Does Ursodeoxycholic Acid Change the Proliferation of the Colorectal Mucosa? A Randomized, Placebo-Controlled Study

Digestion

Volumn 68, Issue 4, 2003, Pages 209-216

  Ochsenkühn, Thomas ^a   Marsteller, Igor ^a   Hay, Ulrich ^a   Diebold, Joachim ^b   Paumgartner, Gustav ^a   Göke, Burkhard ^a   Sackmann, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bile acids; Bile salts; Colorectal cancer, chemoprevention; Colorectal mucosa; Colorectal proliferation; Deoxycholic acid; Lithocholic acid; Randomized placebo controlled study; Ursodeoxycholic acid

Indexed keywords

DEOXYCHOLIC ACID; IODINE; LITHOCHOLIC ACID; PROPIDIUM IODINE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADENOMA; ADULT; AGED; ARTICLE; BIOPSY; BLOOD SAMPLING; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; COLON MUCOSA; COLONOSCOPY; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENDOSCOPIC POLYPECTOMY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM MUCOSA;

ADENOMA; AGED; CELL DIVISION; CHOLAGOGUES AND CHOLERETICS; COLON; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PLACEBOS; RECTUM; URSODEOXYCHOLIC ACID;

EID: 1342344030     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075927     Document Type: Article

References (55)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
2. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, Reid ME, Ritenbaugh C, Vargas PA, Bhattacharyya AB, Earnest DL, Sampliner RE: Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000;342:1156-1162.
3. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, Shike M, Weissfeld J, Burt R, Cooper MR, Kikendall JW, Cahill J: Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342:1149-1155.
4. Gwyn K, Sinicrope FA: Chemoprevention of colorectal cancer. Am J Gastroenterol 2002;97:13-21.
5. Ricciardiello L, Roda E, Bazzoli F: Chemoprevention in colorectal neoplasias: What is practical and feasible? Dig Dis 2002;20:70-72.
6. Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25.
7. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
8. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM: Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology 2002;122:641-645.
9. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
10. Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA: Chemoprevention of azoxymethane-induced colorectal carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994;54:5071-5074.
11. Narisawa T, Fukaura Y, Terada K, Sekiguchi H: Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colorectal mucosal telomerase activity in F344 rats. J Exp Clin Cancer Res 1999;18:259-266.
12. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA: Ursodiol use is associated with lower prevalence of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
13. Kurtz WJ, Guldutuna S, Leuschner U: Differing effect of chenodeoxycholic acid and ursodeoxycholic acid on bile acids in rat colorectal wall and contents. Tokai J Exp Clin Med 1988;13:91-97.
14. Rodrigues CM, Kren BT, Steer CJ, Setchell KD: The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995;109:1835-1844.
15. Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Earnest DL: Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 1998;58:1684-1687.
16. Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS et al: Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-338.
17. Reddy BS, Narasawa T, Weisburger JH, Wynder EL: Promoting effect of sodium deoxycholate on colon adenocarcinomas in germ-free rats. J Natl Cancer Inst 1976;56:441-442.
18. Ochsenkühn T, Bayerdörffer E, Meining A, Schinkel M, Thiede C, Nüssler V, Sackmann M, Hatz R, Neubauer A, Paumgartner G: Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999;85:1664-1669.
19. Lipkin M: Biomarkers of increased susceptibility to gastrointestinal cancer: New application to studies of cancer prevention in human subjects. Cancer Res 1988;48:235-245.
20. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
21. Mannes GA, Stellaard F, Paumgartner G: Diagnostic sensitivity of fasting and postprandial serum bile acids determined by different methods. Clin Chim Acta 1987;162:147-154.
22. Fischbach W, Zidianakis Z, Lüke G, Kirchner T, Mössner J: DNA mapping of colorectal neoplasms: A flow cytometric study of DNA abnormalities and proliferation. Gastroenterology 1993;105:1126-1133.
23. Bortoluzzi F, Valentini M, Cernigoi C, Toffoli G, Boiocchi M, Poletti M et al: DNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: A proposed method for assessing severity of disease. Gut 1995;36:50-54.
24. Hartmann DP, Montgomery EA, Carr NJ, Gupta PK, Azumi N: Flow cytometric DNA analysis of ulcerative colitis using paraffinembedded biopsy specimens: Comparison with morphology and DNA analysis of fresh samples. Am J Gastroenterol 1995;90:590-596.
25. Nishida K, Takano H, Yoneda M, Ohtsuki T, Fujii M, Teresawa Y et al: Flow cytometric analysis of nuclear DNA content in tissues of colon cancer using endoscopic biopsy specimens. J Surg Oncol 1995;59:181-185.
26. Pasricha PJ, Bedi A, O'Connor K, Rashid A, Akktar AJ, Zahurak ML et al: The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995;109:994-998.
27. Porschen R, Robin U, Schumacher A, Schauseil S, Borchard F, Hengels KJ et al: DNA aneuploidy in Crohn's disease and ulcerative colitis: Results of a comparative flow cytometric study. Gut 1992;33:663-667.
28. Bach BA, Knape WA, Edinger MG, Tubbs RR: Improved sensitivity and resolution in the flow cytometric DNA analysis of human solid tumor specimen. Am J Clin Pathol 1991;96:615-627.
29. Setchell KDR, Ives JA, Cashmore GC, Lawson AM: On the homogeneity of stools with respect to bile acid composition and normal day-to-day variations: A detailed qualitative and quantitative study using capillary column gas chromatography-mass spectrometry. Clin Chim Acta 1987;162:257-275.
30. 13C-labelled bile acids. J Lipid Res 1984;25:1313-1319.
31. Karlaganis G, Paumgartner G: Determination of bile acids in serum by capillary gas-liquid chromatography. Clin Chim Acta 1979;92:19-26.
32. Setchell KDR, Matsui A: Serum bile acid analysis. Clin Chim Acta 1982;127:1-17.
33. Stellaard F, Paumgartner G: Measurement of isotope ratios in organic compounds at picomole quantities by capillary gas chromatography/quadrupole electron impact mass spectometry. Biomed Mass Spectrom 1985;12:560-564.
34. Deschner EE, Hallak A, Rozen P, Gilat T: Prolonged administration of bile salts for gallstone dissolution and its effect on rectal epithelial cell proliferation. Dig Dis Sci 1987;32:991-996.
35. Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, Payne CM, Powell MB, Gerner EW, Earnest DL: Different bile acids exhibit distinct biological effects: The tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998;31:111-118.
36. Simanowski UA, Seitz HK, Czygan P, Horner M, Waldherr R, Weber E, Kommerell B: Chronic ursodeoxycholic acid-and chenodeoxycholic acid-feeding-induced changes of colon mucosal cell proliferation in rats. J Natl Cancer Inst 1987;79:163-166.
37. Van Faassen A, Ochsenkühn T, Houterman S, van der Ploeg EM, Bueno-de-Mesquita BH, Ocke MC, Bayerdörffer E, Janknegt RA: Plasma deoxycholic acid is related to deoxycholic acid in faecal water. Cancer Lett 1997;114:293-294.
38. Van Gorkom BA, van der Meer R, Boersmavan Ek W, Termont DS, de Vries EG, Kleibeuker JH: Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: A placebo-controlled cross-over intervention trial in healthy volunteers. Scand J Gastroenterol 2002;37:965-971.
39. Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G: Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and chronic cholestatic liver disease. Hepatology 1992;15:603-608.
40. Stadler J, Yeung KS, Furrer R, Marcon N, Himal HS, Bruce WR: Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colorectal polyps or cancer. Cancer Lett 1988;38:315-320.
41. Bayerdörffer E, Mannes GA, Richter WO, Ochsenkühn T, Wiebecke B, Köpcke W, Paumgartner G: Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993;104:145-151.
42. Suzuki K, Bruce WR: Increase by deoxycholic acid of the colonic nuclear damage induced by known carcinogens in C57BL/6J mice. J Natl Cancer Inst 1986;76:1129-1132.
43. Hori T, Matsumoto K, Sakaitani Y, Sato M, Morotomi M: Effect of dietary deoxycholic acid and cholesterol on fecal steroid concentration and its impact on the colonic crypt cell proliferation in azoxymethane-treated rats. Cancer Lett 1998;124:79-84.
44. Owen RW, Thompson MH, Hill MJ, Wilpart M, Mainguet P, Roberfroid M: The importance of the ratio of lithocholic to deoxycholic acid in large bowel carcinogenesis. Nutr Cancer 1987;9:67-71.
45. Hawk ET, Viner JL: Chemoprevention in ulcerative colitis: Narrowing the gap between clinical practice and research (editorial). Ann Intern Med 2001;134:158-160.
46. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA: The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643-1649.
47. Broome U, Lofberg R, Veress B, Eriksson LS: Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 1995;22:1404-1408.
48. Velázquez OC, Seto RW, Choi J, Zhou D, Breen F, Fisher JD, Rombeau JL: Butyrate inhibits deoxycholate-induced increase in colonic mucosal DNA and protein synthesis in vivo. Dis Colon Rectum 1997;40:1368-1375.
49. Weinmann P, Scharffetter-Kochanek K, Forlow SB, Peters T, Walzog B: A role for apoptosis in the control of neutrophil homeostasis in the circulation: Insights from CD18-deficient mice. Blood 2003;101:739-746.
50. Gloria L, Cravo M, Pinto A, de Sousa LS, Chaves P, Leitao CN, Quina M, Mira FC, Soares J: DNA hypomethylation and proliferative activity are increased in the rectal mucosa of patients with long-standing ulcerative colitis. Cancer 1996;78:2300-2306.
51. Meining A, Hackelsberger A, Daenecke C, Stolte M, Bayerdörffer E, Ochsenkühn T: Increased cell proliferation of the gastric mucosa in first-degree relatives of gastric carcinoma patients. Cancer 1998;83:876-881.
52. Milovic V, Teller IC, Faust D, Caspary WF, Stein J: Effects of deoxycholate on human colon cancer cells: Apoptosis or proliferation. Eur J Clin Invest 2002;32:29-34.
53. Shekels LL, Beste JE, Ho SB: Tauroursodeoxycholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acids. J Lab Clin Med 1996;127:57-66.
54. Serfaty L, DeLeusse A, Rosmorduc O, Desaint B, Flejou JF, Chazouilleres O, Poupon RE, Poupon R: Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: An observational study. Hepatology 2003;38:203-209.
55. Jänne PA, Mayer RJ: Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-1968.